Mazen Mahjoub, MD
Cardiology · Warren, OHNPI 1679512081
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 560 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 13.9% — the pattern of someone who eats at a lot of different presentations.
Across 560 payments — averaging $15.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$1K
- AstraZeneca$1K
- Johnson & Johnson$1K
- Merck$1K
- Boehringer Ingelheim$920
- E.r. Squibb & Sons, L.L.C.$750
- plus $3K from 17 others
What the payments were for
- Food & beverage$8,81599%
- Education$1271%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 93 | $1,243 |
| AstraZeneca | 72 | $1,155 |
| Johnson & Johnson | 69 | $1,035 |
| Merck | 56 | $1,003 |
| Boehringer Ingelheim | 53 | $920 |
| E.r. Squibb & Sons, L.L.C. | 51 | $750 |
| Amgen | 45 | $726 |
| Sanofi-aventis U.S. LLC | 32 | $492 |
| Pfizer | 33 | $369 |
| Boston Scientific | 13 | $264 |
| Novo Nordisk | 11 | $195 |
| Abbott | 5 | $180 |
| Astellas Pharma US Inc | 5 | $153 |
| Esperion Therapeutics, Inc. | 4 | $67 |
| Regeneron Healthcare Solutions, Inc. | 5 | $67 |
| Medtronic | 1 | $65 |
| Edwards Lifesciences | 2 | $64 |
| Bayer | 3 | $62 |
| Kestra Medical Technology Services, Inc. | 2 | $44 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $33 |
| Atricure, Inc. | 1 | $20 |
| Scpharmaceuticals Inc. | 1 | $19 |
| Actelion Pharmaceuticals US, Inc. | 1 | $16 |
How this compares
$8,942 in reported general payments places this provider in the 85th percentile of 30 cardiology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 1,133 | $1,027,232 |
| EntrestoSacubitril/Valsartan | 504 | $479,258 |
| XareltoRivaroxaban | 390 | $380,875 |
| JardianceEmpagliflozin | 205 | $179,085 |
| Repatha SureclickEvolocumab | 67 | $69,193 |
| FarxigaDapagliflozin Propanediol | 58 | $52,747 |
| MultaqDronedarone Hcl | 33 | $39,673 |
| VerquvoVericiguat | 34 | $33,782 |
| Metoprolol Succinate | 1,567 | $18,275 |
| Praluent PenAlirocumab | 17 | $17,106 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 60 | $13,031 |
| Amiodarone Hcl | 362 | $11,214 |
| Dofetilide | 48 | $9,251 |
| Flecainide Acetate | 165 | $7,649 |
| Ranolazine ErRanolazine | 47 | $6,153 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $369 | $1,027,2321,133 claims |
| NovartisEntresto | $1,243 | $479,258504 claims |
| Johnson & JohnsonXarelto | $1,035 | $380,875390 claims |
| Boehringer IngelheimJardiance | $920 | $179,085205 claims |
| AstraZenecaFarxiga | $1,155 | $52,74758 claims |
| Sanofi-aventis U.S. LLCMultaq | $492 | $39,67333 claims |
| MerckVerquvo | $1,003 | $33,78234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 30 cardiology providers in Ohio.
Other cardiology in Warren
- Luis Augusto Palma DallanCleveland$61K
- Rafel El-AtassiElyria$23K
- Haytham MouslyCleveland$17K
- Vinay ChitkaraLondon$8K
- Farshad ForouzandehParma$6K
- Vijay RavipatiColumbus$3K
- Basel MoussaFairview Park$2K
- Robert OkyereCleveland$102
- William MarshallColumbus$0
- Scott MaffettColumbus$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.